Dr. Afshin Dowlati is a medical oncologist at the University Hospitals Seidman Cancer Center and a researcher at Case Comprehensive Cancer Center. As the Director of the Thoracic Oncology Program, he specializes in both the biological and clinical management of thoracic malignancies, with a particular interest in small cell lung cancer and malignant pleural mesothelioma.
Dr. Melinda Hsu is a thoracic medical oncologist at University Hospitals Seidman Cancer Center and an Assistant Professor of Medicine at Case Western Reserve University. She specializes in the care of patients with lung cancer, as well as other thoracic malignancies including malignant pleural mesothelioma. Dr. Hsu’s primary objective is to optimize the care of
Dr. Debora S. Bruno is a thoracic medical oncologist and Medical Director of Clinical Research at the City of Hope Cancer Center in Atlanta, Georgia.She is focused on caring for patients with lung cancer, thymic malignancies, and malignant pleural mesothelioma, with an emphasis on the use of new therapies that improve the time patients have
Dr. Jared Weiss is the Section Chief of Thoracic and Head/Neck Oncology and a Professor of Medicine at the UNC School of Medicine and the UNC Lineberger Comprehensive Cancer Center. He specializes in lung cancer, squamous head and neck cancer, and other cancers including malignant pleural mesothelioma with a focus on the use of immunotherapy,
Dr. Chad Pecot is a thoracic medical oncologist at UNC Health and Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina. He specializes in lung cancer and abnormal tumors inside the chest, including malignant pleural mesothelioma. He chose lung cancer as a specialty because of its lethality, and he is grateful that through research, patients
Dr. Carrie Lee is a thoracic oncologist at the University of North Carolina Health in Chapel Hill, a Professor at UNC School of Medicine, and Director of the Thoracic Oncology Program at UNC Lineberger Comprehensive Cancer Center. Her clinical practice focuses on lung cancer and she has broad experience with traditional chemotherapy protocols as well
A just-released study conducted in the Netherlands provides a mixed assessment of the use of nivolumab-ipilimumab immunotherapy in patients with malignant pleural mesothelioma. While researchers found that the real-world efficacy of the combination was comparable to what was reported in a phase 3 study, they also reported that toxicities – particularly among elderly patients –
Dr. William Petty is a medical oncologist and hematologist in the department of Medical Oncology at the Wake Forest Medical Center and Wake Forest Comprehensive Cancer Center. As Director of the Thoracic Oncology program, he specializes in treating patients diagnosed with lung cancer and malignant pleural mesothelioma. Dr. Petty’s philosophy on taking care of patients
A group of researchers from cancer centers in Vienna has announced that they’ve identified a therapeutic target that, when inhibited, enhances mesothelioma tumors’ sensitivity to chemotherapy and radiotherapy. The group believes that this approach may yield a novel and effective treatment approach for the rare, asbestos-related disease.
Dr. Clarke is a medical oncologist within Duke Health and the Duke Cancer Institute in Durham, North Carolina. He specializes in treating patients with cancers of the chest, including malignant mesothelioma and lung cancer. He says that the most rewarding part of his work is developing long-term relationships with his patients and their families throughout